Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
Cell-culture provider receives investment from Summit Partners
September 9th, 2004
Diagnostic Hybrids, Inc., (DHI), a cell-culture provider, announced that it has received a $10 million minority investment led by Summit Partners, a private-equity and venture-capital firm with more than $5.5 billion in capital under management. Kenson Ventures, LLC, a venture-capital firm focusing on biotechnology and life science investments, also participated in the investment. With this funding, DHI plans to fund new research and development initiatives, expand its facilities, and pursue technology and company acquisitions. Founded in 1983, DHI develops and manufactures genetically engineered tissue cell cultures, monoclonal...
Source: Blood Weekly (2004-09-09)
|
